OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have earned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $24.4444.

A number of brokerages have commented on KIDS. Truist Financial set a $17.00 price objective on shares of OrthoPediatrics in a research note on Friday, May 1st. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. BTIG Research reissued a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a research note on Friday, May 1st. Canaccord Genuity Group set a $25.00 price objective on shares of OrthoPediatrics in a research note on Friday, April 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Tuesday, April 21st.

Insiders Place Their Bets

In related news, insider Gregory A. Odle sold 8,433 shares of OrthoPediatrics stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $145,469.25. Following the completion of the transaction, the insider directly owned 187,735 shares of the company’s stock, valued at approximately $3,238,428.75. The trade was a 4.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David R. Bailey sold 19,535 shares of OrthoPediatrics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $336,978.75. Following the transaction, the chief executive officer directly owned 298,020 shares of the company’s stock, valued at approximately $5,140,845. This represents a 6.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 58,171 shares of company stock worth $1,003,450. Insiders own 32.70% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

A number of large investors have recently made changes to their positions in the company. Quantinno Capital Management LP purchased a new position in shares of OrthoPediatrics during the 1st quarter worth about $160,000. Waverly Advisors LLC purchased a new position in shares of OrthoPediatrics during the 1st quarter worth about $184,000. Granahan Investment Management LLC boosted its stake in shares of OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after purchasing an additional 232,760 shares during the period. Sei Investments Co. boosted its stake in shares of OrthoPediatrics by 31.1% during the 1st quarter. Sei Investments Co. now owns 82,081 shares of the company’s stock worth $1,303,000 after purchasing an additional 19,489 shares during the period. Finally, Roubaix Capital LLC boosted its stake in shares of OrthoPediatrics by 23.8% during the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company’s stock worth $4,603,000 after purchasing an additional 55,724 shares during the period. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Stock Performance

Shares of NASDAQ:KIDS opened at $18.37 on Monday. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $23.70. The stock has a market capitalization of $471.74 million, a P/E ratio of -10.93 and a beta of 0.99. The firm has a fifty day simple moving average of $16.72 and a two-hundred day simple moving average of $17.33. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. The business had revenue of $59.36 million during the quarter, compared to analysts’ expectations of $58.29 million. On average, analysts expect that OrthoPediatrics will post -1.13 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.